CAR-T cells can be effective protein delivery vehicles to treat lymphoma

GSK gene therapy

Researchers at Memorial Sloan Kettering have discovered something new about CAR-T immunotherapy: The cells can act as delivery vehicles for proteins that have the potential to treat lymphoma.

In patients with follicular lymphoma, a receptor called HVEM is mutated half of the time, and the mutations can lead to growth of the cancer. To combat this, the scientists engineered a CAR-T cell to deliver the HVEM protein normally produced by healthy cells. And the CAR-T cell acts as a sort of “micro-pharmacy” that continuously makes the protein locally.

In animal tests, the protein-producing CAR-T cells performed better than the control.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Previously, CAR-T cells were thought to directly attack cancer cells, but the new research, published in Cell, demonstrates they can have even more of an impact.

Suggested Articles

Kintai Therapeutics' anti-obesity candidate KTX-0200 showed sustained weight loss and improved glucose control and liver health in rodents.

Preclinical studies suggest sGC stimulator IW-6463 can improve dendritic spine density, reduce neuroinflammation and increase brain blood flow.

VISTA represents a novel checkpoint regulator that can be targeted by both agonists and antagonists to trigger opposing therapeutic T-cell effects.